Combined MEK and BCL-XL Inhibition Kills KRAS -Mutant Cells

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2012-236
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

Cancer Cell
Cancer ResearchOncologyCell Biology
2013English

Combined Inhibition of Notch Signaling and BCL-2/BCL-xL Results in Synergistic Antimyeloma Effect

Molecular Cancer Therapeutics
Cancer ResearchOncology
2010English

Erratum: Mechanism of MEK Inhibition Determines Efficacy in Mutant KRAS- Versus BRAF-driven Cancers

Nature
Multidisciplinary
2013English

Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer

Cancer Letters
Cancer ResearchOncology
2014English

Apoptosis Is Augmented in High-Grade Serous Ovarian Cancer by the Combined Inhibition of BCL-2/BCL-xL and PARP

International Journal of Oncology
Cancer ResearchOncology
2017English

SHP2 Inhibition Overcomes RTK-mediated Pathway Re-Activation in KRAS Mutant Tumors Treated With MEK Inhibitors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

MEK Nuclear Localization Promotes YAP Stability via Sequestering Β-TrCP in KRAS Mutant Cancer Cells

Cell Death and Differentiation
Cell BiologyMolecular Biology
2019English

KRAS-mutant Colon Cancer Cells Respond to Combined Treatment of ABT263 and Axitinib

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2019English

Combined BRAFV600E and MEK Blockade for BRAFV600E-mutant Gliomas

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy